Arcus Biosciences (RCUS) Accumulated Expenses (2017 - 2023)
Arcus Biosciences (RCUS) posted quarterly Accumulated Expenses of $15.0 million for Q2 2023, up 3.89% year-over-year from $14.4 million in Q2 2022, and up 25.0% quarter-over-quarter from $12.0 million in Q1 2023.
Arcus Biosciences (RCUS) Accumulated Expenses (2017 - 2023) Analysis & Trends
Arcus Biosciences' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $15.0 million for Q2 2023.
- In Q2 2023, Accumulated Expenses rose 3.89% year-over-year to $15.0 million; the TTM figure through Jun 2023 stood at $15.0 million (up 3.89% YoY), while the FY2022 annual figure was $25.0 million, up 47.06% from the prior year.
- Accumulated Expenses for Q2 2023 stood at $15.0 million, up from $12.0 million in the prior quarter.
- The five-year high for Accumulated Expenses was $25.0 million in Q4 2022, with the low at $2.0 million in Q1 2019.
- The 5-year median for Accumulated Expenses is $10.7 million (2021), against an average of $10.7 million.
- The sharpest annual moves came in 2019 and 2020: Accumulated Expenses surged 258.18% in 2019, then slumped 74.41% in 2020.
- Arcus Biosciences' Accumulated Expenses stood at $5.0 million in 2019, then jumped by 92.79% to $9.5 million in 2020, then soared by 78.14% to $17.0 million in 2021, then soared by 47.06% to $25.0 million in 2022, then sank by 40.0% to $15.0 million in 2023.
- Business Quant data shows RCUS's Accumulated Expenses at $15.0 million in Q2 2023, $12.0 million in Q1 2023, and $25.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 15.00 Mn |
| Mar 31, 2023 | 12.00 Mn |
| Dec 31, 2022 | 25.00 Mn |
| Sep 30, 2022 | 18.00 Mn |
| Jun 30, 2022 | 14.44 Mn |
| Mar 31, 2022 | 11.67 Mn |
| Dec 31, 2021 | 17.00 Mn |
| Sep 30, 2021 | 14.63 Mn |
| Jun 30, 2021 | 9.71 Mn |
| Mar 31, 2021 | 7.13 Mn |
| Dec 31, 2020 | 9.54 Mn |
| Sep 30, 2020 | 6.25 Mn |
| Jun 30, 2020 | 3.98 Mn |
| Mar 31, 2020 | 2.57 Mn |
| Dec 31, 2019 | 4.95 Mn |
| Sep 30, 2019 | 3.46 Mn |
| Jun 30, 2019 | 15.55 Mn |
| Mar 31, 2019 | 1.96 Mn |
| Dec 31, 2018 | 2.83 Mn |
| Sep 30, 2018 | 2.76 Mn |